Trachoma is the world's leading infectious cause of blindness, and for three decades a single oral antibiotic has been central to the effort to stop it. This article explains what trachoma actually does to the eye, why azithromycin replaced older treatments, what the clinical trial evidence shows, and where the science remains genuinely unsettled - particularly around antibiotic resistance and an unexpected signal that azithromycin distribution may reduce child mortality more broadly.
What Trachoma Does, and Who It Harms
Trachoma is caused by repeated conjunctival infection with the bacterium Chlamydia trachomatis. A single infection is unremarkable and often clears on its own. The damage comes from repetition: in communities with poor access to water and sanitation, children are reinfected again and again through contact, flies, and shared cloths, and each bout of inflammation leaves a little more scarring on the inner eyelid. Over years, that scarring can pull the eyelashes inward - a condition called trichiasis - so that every blink drags lashes across the cornea. Left untreated, this produces corneal scarring and irreversible blindness, typically appearing in adulthood after a childhood of repeated infection.
The disease falls hardest on the poorest rural communities, and within those communities disproportionately on women, who through caregiving have closer and more prolonged contact with infected children. The World Health Organization has long estimated that many millions of people live in areas where trachoma transmission is still active, and that a substantial number carry trichiasis severe enough to threaten their sight. Every case represents someone - often a grandmother, often a mother of young children - whose remaining years risk being spent in darkness for want of a treatment that costs very little.
From Six Weeks of Ointment to a Single Tablet
For most of the twentieth century, trachoma was treated with topical tetracycline ointment applied twice daily for six weeks. It worked when used correctly, but six weeks of twice-daily eye ointment is a hard regimen to sustain across an entire village, especially among children, and adherence in real-world programs was poor.
The turning point came from a randomized trial conducted in the Gambia by researchers associated with the London School of Hygiene and Tropical Medicine, published in The Lancet in the early 1990s. It found that a single oral dose of azithromycin produced clinical and microbiological cure rates comparable to the full six-week course of topical tetracycline, without requiring sustained daily compliance. Follow-up field studies in Tanzania and Egypt through the 1990s confirmed the finding across different settings. This was not a modest improvement; it converted a logistically difficult household-by-household treatment into something that could be delivered to an entire village in a single afternoon by a community health worker - the precondition for mass drug administration on a national scale.
The SAFE Strategy and the Machinery of Mass Treatment
The World Health Organization organizes trachoma control around an approach known by the acronym SAFE: Surgery for advanced trichiasis, Antibiotics to clear infection, Facial cleanliness to reduce transmission, and Environmental improvement, chiefly access to water and sanitation. Azithromycin is the "A" in that strategy, but the WHO has always been explicit that antibiotics alone do not solve trachoma - without cleaner faces and better water access, reinfection simply resumes.
The scale of drug distribution has depended on a specific act of corporate donation. In 1998, Pfizer and the Edna McConnell Clark Foundation established the International Trachoma Initiative to coordinate free azithromycin donation to national trachoma programs. Over more than two decades, this partnership has facilitated the donation of hundreds of millions of treatment doses across dozens of countries in Africa, the Middle East, Asia, and Latin America. It stands as one of the more durable public-private health partnerships of its kind, built on straightforward logistics: national ministries of health identify endemic districts, community volunteers distribute the drug annually for a period of years, and independent surveys check whether infection prevalence has fallen enough to stop.
The results are measurable. The WHO has formally validated a growing list of countries as having eliminated trachoma as a public health problem, including Morocco, Mexico, Nepal, Cambodia, Laos, Ghana, and China, with further countries following in subsequent years. Validation requires surveys showing that both active infection and trichiasis have fallen below defined thresholds and that health systems can manage any remaining cases. This is not a marketing claim; it is an epidemiological standard applied consistently across countries, and it represents genuine, countable relief from a disease that has blinded people for millennia.
An Unexpected Finding: Azithromycin and Child Mortality
One of the more consequential trials to come out of trachoma research was not, strictly, about trachoma at all. The MORDOR trial - conducted by the Francis I. Proctor Foundation at the University of California, San Francisco, funded by the Bill & Melinda Gates Foundation, and published in the New England Journal of Medicine in 2018 - was a large cluster-randomized trial testing biannual azithromycin distribution to children aged one to fifty-nine months across communities in Niger, Malawi, and Tanzania, none of which were selected for trachoma prevalence. The trial found a reduction in all-cause childhood mortality of roughly one-seventh relative to placebo overall, with the largest effect seen in Niger, where background child mortality was highest.
This is a genuine and important finding, but it deserves careful framing rather than enthusiasm. The mechanism is not fully established - the leading hypothesis is a reduction in the burden of common bacterial and possibly other infections during a period of high vulnerability, rather than any effect specific to trachoma. The WHO has responded cautiously, noting that routine mass distribution of an antibiotic to healthy children for mortality reduction raises different questions than treating an infection that is actually present, and that broader adoption should wait for more data on where the benefit is largest and how resistance risk should be managed. It is a case where a well-designed randomized trial produced a clear signal in humans, while the appropriate policy response remains, quite properly, unresolved.
Resistance: The Honest Cost of Mass Treatment
No discussion of repeated, community-wide antibiotic distribution is complete without addressing resistance. Field studies, including work from the Proctor Foundation published in outlets such as the American Journal of Tropical Medicine and Hygiene, have documented that communities undergoing repeated mass azithromycin distribution show increased carriage of macrolide-resistant strains of common bacteria such as Streptococcus pneumoniae, at least for a period after distribution rounds. Whether this translates into worse clinical outcomes for those communities, and how durable the resistance is once distribution stops, remains an active area of study rather than a settled question.
This is exactly the kind of trade-off that responsible antibiotic stewardship requires acknowledging rather than minimizing. Azithromycin is not deployed in trachoma programs casually; distribution is time-limited, targeted to defined endemic districts, and paired with monitoring precisely because the people running these programs take the resistance question seriously. It is a reasonable illustration of why antibiotics, even when donated freely and used for a clearly worthy purpose, are never a cost-free intervention - a fact that ought to inform how any of us think about antibiotic use, at the community level or in our own family's medicine cabinet.
Perspective on the Compound Itself
It is worth pausing on where azithromycin comes from. It is a semi-synthetic derivative of erythromycin, itself isolated from a soil-dwelling bacterium of the genus Streptomyces. That a molecule traceable to ordinary soil organisms should, through careful chemistry, become the tool that lets a health worker walk into a village and prevent blindness in a single dose is a reminder that the created world still yields remedies to patient, disciplined science. None of this diminishes the responsibility that goes with using it well - dosing accurately, respecting resistance, and treating mass drug administration campaigns as something communities should understand and consent to, not simply receive. Programs that explain what is being given, and why, to village elders and parents tend to sustain trust and participation far better than those that do not.
Key takeaway: Azithromycin turned trachoma control from a difficult six-week regimen into a single-dose intervention that has helped multiple countries eliminate a centuries-old cause of blindness, while ongoing research into its effect on child mortality and antibiotic resistance shows that even a genuine public health success still calls for careful, continuing scrutiny.